FDA Approves Two Alnylam RNAi Therapies
- Posted by ISPE Boston
- On April 3, 2025
Alnylam delivered a one-two punch in March, growing its portfolio of FDA-approved RNAi therapies with the addition of Amvuttra (vutrisiran) for transthyretin amyloid cardiomyopathy (ATTR-CM) and Qfitlia (fitusiran) for hemophilia. Qfitlia (fitusiran) is the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, and […]
Read More